Alvotech has entered key supply and commercialization agreements with Sandoz to expand biosimilar treatments in Canada and across Australia and New Zealand. The deal covers multiple therapeutic areas—ophthalmology, immunology, and gastroenterology—and positions both companies to broaden patient access through shared responsibilities in development, manufacturing, and distribution.